By KIM BELLARD Chances are someone in your family is a gamer. Maybe you are a gamer yourself. After all, somewhere between two-thirds and three-fourths of Americans play video games, and if you just looked at young men, it’d be closer to 100%. Grumpy older people don’t get it, complaining that gaming is just a…
Keros Therapeutics will present Phase 2 data for the drug, elritercept, at the annual meeting of the American Society of Hematology. Meanwhile, the Takeda deal enables Keros to focus on two wholly owned assets, one of which could compete with a Merck drug approved earlier this year. The post Takeda Pays $200M for Keros Therapeutics…
CagriSema, a dual-acting drug in development by Novo Nordisk, met the goal of a Phase 3 test in patients with obesity and type 2 diabetes. But the topline results don’t show an advantage over Eli Lilly’s commercialized obesity medication, Zepbound. The post Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss…
“For too many, coverage is either unavailable or insufficient.” This is the harsh reality the American Hospital Association highlighted in a recent statement to the US Senate, urging action to address growing medical debt. Despite efforts to expand insurance coverage, hospitals continue to lose billions of dollars through unpaid bills. The statement notes that hospitals…
Health care in the United States is confusing for patients and consumers. Price transparency is a step in the right direction — transformative change can happen by combining cost, quality, appropriateness and efficiency measures. The post Healthcare Price Transparency is Not Enough appeared first on MedCity News.
Timely by DrFirst launched a tool to streamline prior authorizations and improve access to specialty medications. The post Timely by DrFirst Aims to Lower Barriers to Specialty Meds appeared first on MedCity News.
Epic’s rollout of a built-in AI charting tool is intensifying competition in the already crowded ambient AI scribe market, forcing standalone vendors to sharpen their differentiation in an Epic-dominated health system landscape. The post Do Ambient Scribe Startups Have a Future Now That Epic Launched Its Own Tool? appeared first on MedCity News.
Greg Herbruck knew 6.5 million of his birds needed to die, and fast. But the CEO of Herbruck’s Poultry Ranch wasn’t sure how the family egg producer (one of the largest in the U.S., in business for over three generations) was going to get through it, financially or emotionally. One staffer broke down in Herbruck’s…
Using Medicare Advantage encounter data, this analysis finds that 62% of Medicare Advantage enrollees have at least one chart review record and that diagnoses added from chart reviews increase payments from CMS to insurers for 17% of enrollees. The use of chart reviews varies across the largest Medicare Advantage insurers.
Leaders of the parent of Anthem and Wellpoint recently agreed with D.C. officials to leave that jurisdiction and say they are focused on long-term financial sustainability.